Order Now
 For Health-Care Providers
Since the introduction of conjugated Hib vaccines, Hib disease has decreased by more than 99%.1 Hib immunization has been such a success story that most new health-care professionals have never seen a case of Hib in their practice. However, because Hib bacteria continue to circulate in the general US population, the disease could easily make a comeback if Hib vaccination stopped.1-3
At ActHIB.com for health-care providers, you can:
Click on the links below to access the information you need.
Coding, Reimbursement and VFC Information 
Slides and Patient Education Materials
Peer-Reviewed Articles on Hib Disease
Report Hib Disease
Indication
ActHIB vaccine is indicated for the active immunization of infants and children 2 through 18 months of age for prevention of invasive Haemophilus influenzae type b disease.
Safety Information
The most common local and systemic adverse reactions to ActHIB vaccine include injection site erythema, swelling, and tenderness; fever irritability, drowsiness, and anorexia. Other adverse reactions may occur. ActHIB vaccine is contraindicated in persons with known hypersensitivity to any component of the vaccine. Vaccination with ActHIB vaccine may not protect all individuals.
Before administering ActHIB vaccine, please see accompanying full Prescribing Information.
[TOP] |
